Hosted on MSN2h
Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside
Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 ...
2 Important Insights From Novo Nordisk's Earnings Call
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Why Novo Nordisk Stock Keeps Going Down
Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...
Novo Nordisk: Dips Like These Come Once Every Few Years
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been ...
Novo Nordisk A/S (NYSE:NVO) Coverage Initiated by Analysts at Morgan Stanley
Morgan Stanley began coverage on shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in a research report released on ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Yahoo Finance3d
Novo Nordisk stock is having a rough week after that Hims & Hers Super Bowl ad
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s dominance over the weight-loss industry. The Danish pharma giant ...
Novo Nordisk missed its diversity targets last year, and its CEO paid a financial price
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
Novo Nordisk: 2024 Earnings Review
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Nasdaq3d
Why Novo Nordisk Stock Keeps Going Down
Novo Nordisk (NYSE: NVO) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, beginning with a 3% decline on Monday from last Friday's close, and falling ...